Evidence map›Paper›PMID 35764754›Full record

ArticlePharmaceutical research2022

Biodegradable and Inherently Fluorescent pH-Responsive Nanoparticles for Cancer Drug Delivery.

Kalindu Perera, Dat X Nguyen, Dingbowen Wang, Aneetta E Kuriakose, Jian Yang, Kytai T Nguyen, Jyothi U Menon

Open access · greenAbstract read
In one paragraph

Article in Pharmaceutical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Current clinical applications and future developments of platinum-based anticancer drugs.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2026
    Review
  2. Stimuli-responsive bioengineered platforms for precision cancer therapy.Frontiers in bioengineering and biotechnology · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Kalindu PereraDepartment of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, 7 Greenhouse Road, Kingston, Rhode Island, 02881, USA.
Dat X NguyenBioengineering Department, The University of Texas at Arlington, Arlington, Texas, 76019, USA.
Dingbowen WangDepartment of Biomedical Engineering, Pennsylvania State University, University Park, Pennsylvania, 16802, USA.
Aneetta E KuriakoseBioengineering Department, The University of Texas at Arlington, Arlington, Texas, 76019, USA.
Jian YangDepartment of Biomedical Engineering, Pennsylvania State University, University Park, Pennsylvania, 16802, USA.
Kytai T NguyenBioengineering Department, The University of Texas at Arlington, Arlington, Texas, 76019, USA.
Jyothi U MenonDepartment of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, 7 Greenhouse Road, Kingston, Rhode Island, 02881, USA. jmenon@uri.edu.ORCID http://orcid.org/0000-0002-0762-3513
The University of Texas at Arlington · USPennsylvania State University · USUniversity of Rhode Island · US

Funding

Citrate Metabonegenic Regulation for the next Generation of Orthopedic Biomaterial DesignR01AR072731 · NIAMS · PENNSYLVANIA STATE UNIVERSITY, THE · PI YANG, JIAN · 2018 to 2022
$1.7M
Nanoparticle-mediated targeting of hepatic macrophages to mitigate inflammation in alcoholic liver diseaseR21AA029750 · NIAAA · UNIVERSITY OF RHODE ISLAND · PI MENON, JYOTHI UNNIKRISHNA · 2022 to 2023
$413k
CPRIT RP210206NIAAA NIH HHS R21 AA029750NIAAA NIH HHS R21AA029750-01NIAMS NIH HHS 1R01AR072731-01NIAMS NIH HHS R01 AR072731Rhode Island Foundation #20174376
6 · The paper itself

Abstract

purposeThe development of two novel pH-only and pH- and thermo-responsive theranostic nanoparticle (NP) formulations to deliver an anticancer drug and track the accumulation and therapeutic efficacy of the formulations through inherent fluorescence.

methodsA pH-responsive formulation was synthesized from biodegradable photoluminescent polymer (BPLP) and sodium bicarbonate (SBC) via an emulsion technique, while a thermoresponsive BPLP copolymer (TFP) and SBC were used to synthesize a dual-stimuli responsive formulation via free radical co-polymerization. Cisplatin was employed as a model drug and encapsulated during synthesis. Size, surface charge, morphology, pH-dependent fluorescence, lower critical solution temperature (LCST; TFP NPs only), cytocompatibility and in vitro uptake, drug release kinetics and anticancer efficacy were assessed.

resultsWhile all BPLP-SBC and TFP-SBC combinations produced spherical nanoparticles of a size between 200-300 nm, optimal polymer-SBC ratios were selected for further study. Of these, the optimal BPLP-SBC formulation was found to be cytocompatible against primary Type-1 alveolar epithelial cells (AT1) up to 100 μg/mL, and demonstrated sustained drug release over 14 days, dose-dependent uptake, and marked pH-dependent A549 cancer cell killing (72 vs. 24% cell viability, at pH 7.4 vs. 6.0). The optimal TFP-SBC formulation showed excellent cytocompatibility against AT1 cells up to 500 μg/mL, sustained release characteristics, dose-dependent uptake, pH-dependent (78% at pH 7.4 vs. 64% at pH 6.0 at 37°C) and marked temperature-dependent A549 cancer cell killing (64% at 37°C vs. 37% viability at pH 6.0, 41°C).

conclusionsIn all, both formulations hold promise as inherently fluorescent, stimuli-responsive theranostic platforms for passively targeted anti-cancer therapy.

Indexed as

Antineoplastic AgentsNanoparticlesNeoplasmsDrug CarriersDrug Delivery SystemsDrug LiberationHumansHydrogen-Ion ConcentrationPolymersAntineoplastic AgentsDrug CarriersPolymersfluorescentnanoparticlespH-sensitivetheranosticthermoresponsive

Identifiers

PMID35764754
PMCPMC9633373
OpenAlexW4283691474

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.